Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma by John, Wagstaff
 Cronfa -  Swansea University Open Access Repository
   
_____________________________________________________________
   
This is an author produced version of a paper published in:
New England Journal of Medicine
                                            
   
Cronfa URL for this paper:
http://cronfa.swan.ac.uk/Record/cronfa25003
_____________________________________________________________
 
Paper:
Motzer, R., Escudier, B., McDermott, D., George, S., Hammers, H., Srinivas, S., Tykodi, S., Sosman, J., Procopio, G.,
et. al. (2015).  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine,
373(19), 1803-1813.
http://dx.doi.org/10.1056/NEJMoa1510665
 
 
 
 
 
 
 
_____________________________________________________________
  
This item is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms
of the repository licence. Copies of full text items may be used or reproduced in any format or medium, without prior
permission for personal research or study, educational or non-commercial purposes only. The copyright for any work
remains with the original author unless otherwise specified. The full-text must not be sold in any format or medium
without the formal permission of the copyright holder.
 
Permission for multiple reproductions should be obtained from the original author.
 
Authors are personally responsible for adhering to copyright and publisher restrictions when uploading content to the
repository.
 
http://www.swansea.ac.uk/iss/researchsupport/cronfa-support/ 
 T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med nejm.org 1
The authors’ full names, academic de-
grees, and affiliations are listed in the Ap-
pendix. Address reprint requests to Dr. 
Motzer at Memorial Sloan Kettering 
 Cancer Center, Memorial Hospital, 1275 
York Ave., New York, NY 10021, or at 
 motzerr@ mskcc . org; or to Dr. Sharma 
at M.D. Anderson Cancer Center, 1515 
Holcombe Blvd., Houston, TX 77030, or 
at  padsharma@ mdanderson . org.
* A complete list of investigators in the 
CheckMate 025 study is provided in the 
Supplementary Appendix, available at 
NEJM.org
This article was published on September 25, 
2015, at NEJM.org.
DOI: 10.1056/NEJMoa1510665
Copyright © 2015 Massachusetts Medical Society.
BACKGROUND
Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated 
with encouraging overall survival in uncontrolled studies involving previously 
treated patients with advanced renal-cell carcinoma. This randomized, open-label, 
phase 3 study compared nivolumab with everolimus in patients with renal-cell 
carcinoma who had received previous treatment.
METHODS
A total of 821 patients with advanced clear-cell renal-cell carcinoma for which they 
had received previous treatment with one or two regimens of antiangiogenic 
therapy were randomly assigned (in a 1:1 ratio) to receive 3 mg of nivolumab per 
kilogram of body weight intravenously every 2 weeks or a 10-mg everolimus tablet 
orally once daily. The primary end point was overall survival. The secondary end 
points included the objective response rate and safety.
RESULTS
The median overall survival was 25.0 months (95% confidence interval [CI], 21.8 
to not estimable) with nivolumab and 19.6 months (95% CI, 17.6 to 23.1) with 
everolimus. The hazard ratio for death with nivolumab versus everolimus was 
0.73 (98.5% CI, 0.57 to 0.93; P = 0.002), which met the prespecified criterion for 
superiority (P≤0.0148). The objective response rate was greater with nivolumab 
than with everolimus (25% vs. 5%; odds ratio, 5.98 [95% CI, 3.68 to 9.72]; 
P<0.001). The median progression-free survival was 4.6 months (95% CI, 3.7 to 5.4) 
with nivolumab and 4.4 months (95% CI, 3.7 to 5.5) with everolimus (hazard ratio, 
0.88; 95% CI, 0.75 to 1.03; P = 0.11). Grade 3 or 4 treatment-related adverse events 
occurred in 19% of the patients receiving nivolumab and in 37% of the patients 
receiving everolimus; the most common event with nivolumab was fatigue (in 2% 
of the patients), and the most common event with everolimus was anemia (in 8%).
CONCLUSIONS
Among patients with previously treated advanced renal-cell carcinoma, overall sur-
vival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than 
with everolimus. (Funded by Bristol-Myers Squibb; CheckMate 025 ClinicalTrials.gov 
number, NCT01668784.)
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Each year, an estimated 338,000 new cases of renal-cell carcinoma are diag-nosed worldwide,1 and approximately 30% 
of patients present with metastatic disease at the 
time of diagnosis.2 A number of targeted thera-
pies have been approved for the treatment of ad-
vanced or metastatic renal-cell carcinoma. These 
agents include vascular endothelial growth fac-
tor (VEGF) pathway inhibitors and mammalian 
target of rapamycin (mTOR) inhibitors.3,4 Evero-
limus is an mTOR inhibitor that is recommend-
ed for the treatment of advanced renal-cell carci-
noma after treatment with sorafenib or sunitinib 
has failed.3-6 Although everolimus and other 
agents have changed the therapeutic landscape 
for this disease, these treatments are associated 
with limited overall survival after a given agent 
is no longer effective.
Nivolumab is a fully human IgG4 programmed 
death 1 (PD-1) immune checkpoint inhibitor 
antibody that selectively blocks the interaction 
between PD-1, which is expressed on activated 
T cells, and PD-1 ligand 1 (PD-L1) and 2 (PD-L2), 
which are expressed on immune cells and tumor 
cells. Interaction between PD-1 and PD-L1 or 
PD-L2 normally results in inhibition of the cel-
lular immune response.7-9 Previous studies have 
shown that PD-L1 expression is associated with 
a poor prognosis in renal-cell carcinoma, pre-
sumably because of its immunosuppressive 
function.10-12 It has been postulated that PD-L1 
expression would be associated with improved 
overall survival in response to nivolumab thera-
py, because disruption of PD-1–PD-L1 signaling 
mediated by nivolumab leads to restored antitu-
mor immunity.13,14
In a phase 2 dose-ranging trial involving pre-
viously treated patients with metastatic renal-
cell carcinoma, nivolumab was found to produce 
objective responses in 20 to 22% of the patients 
and overall survival ranging from 18.2 to 25.5 
months.15 Here, we report results from a phase 
3 study comparing nivolumab with everolimus in 
the treatment of patients with previously treated 
advanced renal-cell carcinoma.
Me thods
Patients
Eligible patients were 18 years of age or older, 
had histologic confirmation of advanced or meta-
static renal-cell carcinoma with a clear-cell com-
ponent and measurable disease according to the 
Response Evaluation Criteria in Solid Tumors 
(RECIST version 1.1),16 and had received one or 
two previous regimens of antiangiogenic thera-
py. Additional inclusion criteria were no more 
than three total previous regimens of systemic 
therapy, including cytokines and cytotoxic che-
motherapy drugs, and disease progression during 
or after the last treatment regimen and within 
6 months before study enrollment. All patients 
had a Karnofsky performance status of at least 
70 at the time of study entry (Karnofsky perfor-
mance status scores range from 0 to 100, with 
higher scores indicating better functioning).17 
Key exclusion criteria were metastasis to the cen-
tral nervous system, previous treatment with an 
mTOR inhibitor, or a condition requiring treat-
ment with glucocorticoids (equivalent to >10 mg 
of prednisone daily).
Study Design
This was a randomized, open-label, phase 3 study 
of nivolumab in comparison with everolimus. 
Randomization (in a 1:1 ratio) was performed 
with a block size of 4, with stratification accord-
ing to region (United States or Canada, Western 
Europe, and the rest of the world), Memorial 
Sloan Kettering Cancer Center (MSKCC) prog-
nostic risk group, and the number of previous 
antiangiogenic therapy regimens (one or two) 
for advanced renal-cell carcinoma. The MSKCC 
prognostic risk is based on the presence of zero 
(favorable risk), one or two (intermediate risk), 
or three (poor risk) of the following prognostic 
factors: anemia, hypercalcemia, and poor perfor-
mance status.18
Nivolumab and everolimus were provided by 
the sponsor, except in cases in which everolimus 
was procured as a local commercial product in 
certain countries. Nivolumab was administered 
at a dose of 3 mg per kilogram of body weight 
as a 60-minute intravenous infusion every 2 weeks. 
Everolimus was administered orally as a daily 
dose of 10 mg. Dose modifications were not per-
mitted for nivolumab but were permitted for evero-
limus.
Study Oversight
This study was approved by the institutional re-
view board or an independent ethics committee 
at each center and was conducted in accordance 
with Good Clinical Practice guidelines, as defined 
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by the International Conference on Harmonisa-
tion. All the patients provided written informed 
consent that was based on the principles of the 
Declaration of Helsinki. A data and safety mon-
itoring committee reviewed efficacy and safety 
during the study.
The study was designed by the authors in col-
laboration with the sponsor (Bristol-Myers Squibb). 
The authors vouch for the accuracy and complete-
ness of the analyses reported and for the fidelity 
of the study to the protocol, which is available 
with the full text of this article at NEJM.org. The 
development of the first draft of the manuscript 
was led by the first author. All the authors con-
tributed to the drafting of the manuscript and 
provided final approval to submit the manuscript 
for publication. Medical-writing support, funded 
by the sponsor, was provided by PPSI.
End Points and Assessments
The primary end point was overall survival, 
which was defined as the time from randomiza-
tion to the date of death. Secondary end points 
included the objective response rate, progres-
sion-free survival, the association between over-
all survival and tumor expression of PD-L1, and 
the incidence of adverse events. Disease assess-
ments were performed with the use of computed 
tomography or magnetic resonance imaging at 
baseline, every 8 weeks for the first year, and 
then every 12 weeks until disease progression or 
discontinuation of treatment. Imaging data were 
evaluated by the investigator to assess tumor 
response (according to RECIST version 1.1). Pa-
tients were allowed to continue the study thera-
py after initial disease progression if a clinical 
benefit as assessed by the investigator was noted 
and the study drug had an acceptable side-effect 
profile. Safety assessments were conducted at 
each clinic visit. After discontinuation of treat-
ment, patients were followed every 3 months for 
assessment of survival and subsequent antican-
cer therapy.
The objective response rate (investigator- 
assessed) was defined as the number of patients 
with a complete response or a partial response 
divided by the number of patients who under-
went randomization. The best overall response 
was defined as the investigator-assessed best re-
sponse (complete response, partial response, sta-
ble disease, or progressive disease) from the time 
of randomization to objectively documented dis-
ease progression or subsequent therapy, which-
ever occurred first. Progression-free survival was 
defined as the time from randomization to first 
documented RECIST-defined tumor progression 
or death from any cause. Tumor PD-L1 membrane 
expression (≥1% vs. <1% and ≥5% vs. <5%) was 
assessed at a central laboratory in sections that 
had at least 100 tumor cells that could be evalu-
ated and were positive for PD-L1 expression, as 
assessed with Dako PD-L1 immunohistochemi-
cal staining in accordance with the manufac-
turer’s instructions.19
Adverse events were graded according to the 
National Cancer Institute Common Terminology 
Criteria for Adverse Events, version 4.0.20 Quality 
of life was assessed with the use of the Functional 
Assessment of Cancer Therapy Kidney Symptom 
Index–Disease-Related Symptoms (FKSI-DRS) 
scoring algorithm.21 The FKSI-DRS questionnaire 
consists of nine symptom-specific questions 
that address lack of energy, pain, weight loss, 
bone pain, fatigue, dyspnea, cough, fevers, and 
hematuria. A summary score ranges from 0 to 36, 
with 36 as the best possible score (no symptoms) 
and 0 as the worst possible score (all the worst 
symptoms).21 Additional details are provided in the 
Supplementary Appendix, available at NEJM.org.
Statistical Analysis
This planned interim analysis was conducted 
after 398 of the 569 deaths (70%) required for 
the final analysis had occurred; the stopping 
boundary was derived on the basis of the number 
of deaths with the use of an O’Brien–Fleming al-
pha-spending function that provided 90% power 
to detect a hazard ratio of 0.76 with an overall 
type I error rate of 0.05 (two-sided).22 Interim 
overall survival was projected at a 0.0148 nomi-
nal significance level; if the results for overall 
survival were significant at that level, the study 
could be stopped at the recommendation of the 
data monitoring committee and declared to be 
positive for efficacy. The interim analysis would 
then be considered the final analysis. In July 2015, 
the study was stopped early because an assess-
ment conducted by the independent data moni-
toring committee concluded that the study had 
met its end point with regard to significant re-
sults for overall survival.
All patients who underwent randomization 
were included in the efficacy analyses; patients 
who received one or more doses of study drug 
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were included in the safety analyses. Overall 
survival, progression-free survival, and the dura-
tion of response were estimated with the use of 
Kaplan–Meier methods.16 Medians and corre-
sponding 95% confidence intervals were deter-
mined with Brookmeyer and Crowley methods23; 
95% confidence intervals were constructed by 
means of a log–log transformation. A stratified 
log-rank test was performed to compare the 
nivolumab group with the everolimus group 
with respect to overall survival and progression-
free survival. We obtained a stratified hazard 
ratio and confidence interval for nivolumab ver-
sus everolimus by fitting a stratified Cox model 
with the group variable as a single covariate. The 
difference in response rates between the 
nivolumab group and the everolimus group 
along with the two-sided 95% confidence inter-
val were estimated with the Cochran–Mantel–
Haenszel method of weighting, with adjustment 
for the stratification factors.24 Survival was com-
pared between the treatment groups with the 
use of the interim analysis monitoring feature of 
East software, version 5.4 (Cytel), which is based 
on the Lan–DeMets error-spending-function ap-
proach, with an O’Brien–Fleming stopping 
boundary used to reject the null hypothesis (i.e., 
that there is no treatment difference), while 
maintaining a two-sided overall alpha level of 
0.05.22 If superiority with regard to the primary 
end point was demonstrated, a hierarchical sta-
tistical testing procedure was followed for the 
objective response rate (estimated along with the 
exact 95% confidence interval with the use of 
the Clopper–Pearson method25) and progression-
free survival at an alpha level of 0.05. For quali-
ty-of-life assessments, descriptive statistics were 
used to assess completion rates and changes in 
quality of life. Wilcoxon–Mann–Whitney tests 
were used to evaluate the between-group differ-
ences in the median change from baseline in 
quality-of-life scores.
R esult s
Patients
From October 2012 through March 2014, a total 
of 821 patients were randomly assigned to a 
treatment group at 146 sites in 24 countries in 
North America, Europe, Australia, South Ameri-
ca, and Asia; 803 of the 821 patients who under-
went randomization were treated — 406 in the 
nivolumab group and 397 in the everolimus 
group. At data cutoff (June 2015), 67 of the 406 
patients (17%) in the nivolumab group and 28 of 
the 397 patients (7%) in the everolimus group 
continued to receive treatment (Fig. S1 in Sup-
plementary Appendix). The minimum follow-up 
period was 14 months. The primary reason for 
discontinuation of treatment was disease pro-
gression (285 of 406 patients [70%] in the 
nivolumab group and 273 of 397 patients [69%] 
in the everolimus group) (Fig. S1 in Supplemen-
tary Appendix). The demographic and clinical 
characteristics of the patients were balanced 
between the treatment groups; the majority of 
patients (72%) had received one previous regi-
men of antiangiogenic therapy for advanced re-
nal-cell carcinoma (Table 1).
Efficacy
Overall Survival
The median overall survival was 25.0 months 
(95% confidence interval [CI], 21.8 to not esti-
mable) in the nivolumab group and 19.6 months 
(95% CI, 17.6 to 23.1) in the everolimus group 
(Fig. 1). Death occurred in 183 of the 410 pa-
tients (45%) randomly assigned to receive 
nivolumab and in 215 of the 411 patients (52%) 
randomly assigned to receive everolimus. The 
hazard ratio for death (from any cause) with 
nivolumab versus everolimus was 0.73 (98.5% 
CI, 0.57 to 0.93; P = 0.002), which met the pre-
specified criterion for superiority. The overall 
survival benefit with nivolumab was observed 
across prespecified subgroups, including sub-
groups defined according to region, MSKCC 
prognostic score, and number of previous regi-
mens of antiangiogenic therapy (Fig. 2A). The 
heterogeneity of the treatment effect within each 
subgroup shown in Figure 2A was tested with 
the use of an interaction test in a Cox propor-
tional-hazards model with treatment, subgroup, 
and treatment-by-subgroup interaction as covari-
ates. None of the interaction terms were signifi-
cant at the 0.05 level.
Tumor Response and Progression-free Survival
The objective response rate was higher with 
nivolumab than with everolimus (25% vs. 5%; 
odds ratio 5.98; 95% CI, 3.68 to 9.72; P<0.001) 
(Table S1 in the Supplementary Appendix). Par-
tial responses were observed in 99 patients 
(24%) in the nivolumab group and in 20 patients 
(5%) in the everolimus group. Complete respons-
es were observed in 4 patients (1%) in the nivolu-
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Characteristic
Nivolumab Group 
(N = 410)
Everolimus Group 
(N = 411)
Total 
(N = 821)
Median age (range) — yr 62 (23–88) 62 (18–86) 62 (18–88)
Sex — no. (%)
Male 315 (77) 304 (74) 619 (75)
Female 95 (23) 107 (26) 202 (25)
Race — no. (%)*
White 353 (86) 367 (89) 720 (88)
Asian 42 (10) 32 (8) 74 (9)
Black 1 (<1) 4 (1) 5 (1)
Other 14 (3) 8 (2) 22 (3)
MSKCC risk group — no. (%)†
Favorable 145 (35) 148 (36) 293 (36)
Intermediate 201 (49) 203 (49) 404 (49)
Poor 64 (16) 60 (15) 124 (15)
Karnofsky performance status — no. (%)‡
<70 2 (<1) 1 (<1) 3 (<1)
70 22 (5) 30 (7) 52 (6)
80 110 (27) 116 (28) 226 (28)
90 150 (37) 130 (32) 280 (34)
100 126 (31) 134 (33) 260 (32)
Disease sites that could be evaluated — no. (%)
1 68 (17) 71 (17) 139 (17)
≥2 341 (83) 338 (82) 679 (83)
Site of metastasis — no. (%)
Lung 278 (68) 273 (66) 551 (67)
Liver 100 (24) 87 (21) 187 (23)
Bone 76 (19) 70 (17) 146 (18)
Previous nephrectomy — no. (%)
Yes 364 (89) 359 (87) 723 (88)
No 46 (11) 52 (13) 98 (12)
Median time from initial diagnosis to randomization 
(range) — mo
31 (1–392) 31 (2–372) 31 (1–392)
Previous antiangiogenic regimens for treatment of  
advanced renal-cell carcinoma — no. (%)
1 294 (72) 297 (72) 591 (72)
2 116 (28) 114 (28) 230 (28)
Previous systemic cancer therapy for metastatic  
renal-cell carcinoma — no. (%)§
Sunitinib 246 (60) 242 (59) 488 (59)
Pazopanib 119 (29) 131 (32) 250 (30)
Axitinib 51 (12) 50 (12) 101 (12)
Patients with quantifiable PD-L1 expression — no. (%) 370 (90) 386 (94) 756 (92)
PD-L1 expression level¶
≥1% 94 (25) 87 (23) 181 (24)
<1% 276 (75) 299 (77) 575 (76)
≥5% 44 (12) 41 (11) 85 (11)
<5% 326 (88) 345 (89) 671 (89)
Patients without quantifiable PD-L1 expression — no. (%) 40 (10) 25 (6) 65 (8)
*  Race was self-reported.
†  The Memorial Sloan Kettering Cancer Center (MSKCC) prognostic risk groups are based on the presence of 0 (favorable),  
1 or 2 (intermediate), or 3 (poor) of the following prognostic factors: anemia, hypercalcemia, and poor performance status.
‡  Karnofsky performance status scores range from 0 to 100, with higher scores indicating better functioning. All patients 
had a Karnofsky performance status of 70 or higher at time of study entry, which may have decreased at randomization.
§  Therapeutic agents that were received by more than 10% of all patients who underwent randomization are included.
¶  The expression level is expressed as the percentage of membrane immunohistochemical staining in 100 or more tumor cells.
Table 1. Baseline Demographic and Clinical Characteristics of the Patients Who Underwent Randomization.
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mab group and in 2 patients (<1%) in the evero-
limus group. The median time to response was 
3.5 months (range, 1.4 to 24.8) among the 103 
patients with a response in the nivolumab group 
and 3.7 months (range, 1.5 to 11.2) among the 
22 patients with a response in the everolimus 
group; the median duration of response was 
12.0 months (range, 0 to 27.6) with nivolumab 
and 12.0 months (range, 0 to 22.2) with everoli-
mus (Table S1 in the Supplementary Appendix). 
Among the patients with a treatment response, 
49 patients (48%) in the nivolumab group and 10 
(45%) in the everolimus group had an ongoing 
response; 32 patients (31%) in the nivolumab 
group and 6 (27%) in the everolimus group had 
an ongoing response for 12 months or longer 
(Fig. S2 in Supplementary Appendix).
The median progression-free survival was 4.6 
months (95% CI, 3.7 to 5.4) in the nivolumab 
group and 4.4 months (95% CI, 3.7 to 5.5) in the 
everolimus group (hazard ratio, 0.88; 95% CI, 
0.75 to 1.03; P = 0.11) (Fig. 2B). To explore the 
apparent delayed separation of the curves, we 
performed an ad hoc sensitivity analysis of pro-
gression-free survival in patients who had not 
had disease progression or died at 6 months 
(145 patients [35%] in the nivolumab group and 
129 patients [31%] in the everolimus group). The 
analysis of this subgroup of patients yielded a 
median progression-free survival of 15.6 months 
(95% CI, 11.8 to 19.6) in the nivolumab group 
and 11.7 months (95% CI, 10.9 to 14.7) in the 
everolimus group (hazard ratio, 0.64; 95% CI, 
0.47 to 0.88).
PD-L1 Expression
Of the 821 patients who underwent randomiza-
tion, 756 (92%) had quantifiable tumor PD-L1 
expression in pretreatment samples: 370 of the 
410 patients (90%) in the nivolumab group and 
386 of the 411 patients (94%) in the everolimus 
group (Table 1). In total, 181 of the 756 patients 
(24%) with quantifiable PD-L1 expression had 
1% or greater PD-L1 expression, and 575 (76%) 
had less than 1% PD-L1 expression (Table 1). 
Among patients with 1% or greater PD-L1 ex-
pression, the median overall survival was 21.8 
months (95% CI, 16.5 to 28.1) in the nivolumab 
group and 18.8 months (95% CI, 11.9 to 19.9) in 
the everolimus group (hazard ratio, 0.79; 95% 
CI, 0.53 to 1.17) (Fig. 3A). Among patients with 
less than 1% PD-L1 expression, the median over-
all survival was 27.4 months (95% CI, 21.4 to not 
estimable) in the nivolumab group and 21.2 
months (95% CI, 17.7 to 26.2) in the everolimus 
group (hazard ratio, 0.77; 95% CI, 0.60 to 0.97) 
(Fig. 3B). Similar results were observed among 
patients with 5% or greater PD-L1 expression, as 
compared with patients with less than 5% PD-L1 
expression, although the interpretation of these 
data is limited by the small numbers of patients 
with 5% or greater expression (Fig. S3 in Supple-
mentary Appendix).
Treatment Administration and Safety
The median duration of treatment was 5.5 months 
(range, <0.1 to 29.6) with nivolumab and 3.7 
months (range, 0.2 to 25.7) with everolimus. In 
total, 207 of the 406 patients treated with 
nivolumab (51%) had dose delays, and 262 of the 
397 patients treated with everolimus (66%) had 
dose delays (including interruptions). A total of 
102 of the 397 patients in the everolimus group 
(26%) had at least one dose reduction; dose re-
ductions were not allowed with nivolumab.
Treatment-related adverse events of any grade 
occurred in 319 of the 406 patients (79%) treat-
ed with nivolumab and in 349 of the 397 pa-
tients (88%) treated with everolimus (Table 2). 
The most common treatment-related adverse 
events among patients who received nivolumab 
Figure 1. Kaplan–Meier Curve for Overall Survival.
CI denotes confidence interval, and NE not estimable.
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were fatigue (134 patients, 33%), nausea (57 
patients, 14%), and pruritus (57 patients, 14%); 
among patients who received everolimus, the 
most common events were fatigue (134 patients, 
34%), stomatitis (117 patients, 29%), and anemia 
(94 patients, 24%). Grade 3 or 4 treatment-relat-
ed adverse events occurred in 76 of the 406 pa-
tients (19%) treated with nivolumab and in 145 
of the 397 patients (37%) treated with everolim-
us; the most common grade 3 or grade 4 event 
Figure 2. Overall Survival in Subgroup Analyses and Kaplan–Meier Curve for Progression-free Survival.
The Memorial Sloan Kettering Cancer Center (MSKCC) prognostic risk groups are based on the presence of 0 (fa-
vorable), 1 or 2 (intermediate), or 3 (poor) of the following prognostic factors: anemia, hypercalcemia, and poor 
performance status. The analyses in Panel A are based on data collected with the use of an interactive voice re-
sponse system.
A Subgroup Analyses of Overall Survival
B Kaplan–Meier Curve for Progression-free Survival
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was fatigue (10 patients, 2%) with nivolumab 
and anemia (31 patients, 8%) with everolimus.
Treatment-related adverse events leading to 
treatment discontinuation occurred in 31 of the 
406 patients (8%) treated with nivolumab and in 
52 of the 397 patients (13%) treated with evero-
limus. No deaths from study-drug toxic effects 
were reported in the nivolumab group, and two 
deaths were reported in the everolimus group 
(one from septic shock and one from acute 
bowel ischemia). A total of 179 of the 406 pa-
tients (44%) who received nivolumab and 183 of 
the 397 patients (46%) who received everolimus 
received treatment beyond initial RECIST version 
1.1–defined progression because, as assessed by 
the investigator, they continued to derive clinical 
benefit from the treatment.
Quality of Life
The FKSI-DRS questionnaire completion rate 
was 80% or higher throughout the first year of 
the study (Table S2 in Supplementary Appendix). 
The median FKSI-DRS quality-of-life score was 
31.0 in both treatment groups at baseline. The 
median changes from baseline in the FKSI-DRS 
score in the nivolumab group increased over 
time and differed significantly from the median 
changes in the everolimus group at each assess-
ment point through week 104 (P<0.05) (Table S2 
in Supplementary Appendix).
Subsequent Therapy
Among the 821 patients who underwent random-
ization, 227 of the 410 patients (55%) in the 
nivolumab group and 260 of the 411 patients (63%) 
in the everolimus group received subsequent sys-
temic therapy. The most common therapeutic 
agents used after treatment with nivolumab 
were everolimus (105 patients, 26%), axitinib (99 
patients, 24%), and pazopanib (37 patients, 9%); 
the most common agents used after treatment 
with everolimus were axitinib (149 patients, 36%), 
pazopanib (64 patients, 16%), and sorafenib 
(38 patients, 9%). Anti–PD-1 therapy was given 
as subsequent therapy to 7 patients in the evero-
limus group.
Discussion
This phase 3 randomized study showed that 
patients with advanced renal-cell carcinoma who 
had received previous antiangiogenic treatment 
had longer survival with nivolumab treatment 
than with everolimus treatment. The separation 
of the overall survival curves occurred early in 
the study, and the median overall survival was 
5.4 months longer with nivolumab than with 
everolimus (25.0 months vs. 19.6 months), a dif-
ference that crossed the prespecified boundary 
for significance at the time of the interim analysis.
Figure 3. Kaplan–Meier Curve for Overall Survival, According to Programmed 
Death 1 Ligand (PD-L1) Expression Level.
A Patients with ≥1% PD-L1 Expression
B Patients with <1% PD-L1 Expression
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This study also showed a higher number of 
objective responses with nivolumab than with 
everolimus, many of which were durable. The 
median progression-free survival was similar in 
the two treatment groups and was consistent 
with that reported in an uncontrolled study in-
volving patients who had previously received 
antiangiogenic therapy.15 Moreover, the results 
of a comparison of progression-free survival 
between the nivolumab group and the everoli-
mus group suggest that progression-free survival 
was not a surrogate for overall survival in this 
study. The late separation of the progression-free 
survival curves suggested a potential delayed 
benefit in progression-free survival with nivolum-
ab. This delayed benefit was subsequently quanti-
fied in a sensitivity analysis that included pa-
tients who had not had disease progression or 
died at 6 months; the median progression-free 
survival was longer with nivolumab than with 
everolimus in this subgroup of patients. These 
patients probably contributed to the overall sur-
vival benefit that was observed with nivolumab 
in this study.
We observed consistently prolonged survival 
with nivolumab, as compared with everolimus, 
irrespective of the MSKCC prognostic score, 
number of previous antiangiogenic therapies, or 
region. A benefit was observed with nivolumab 
irrespective of PD-L1 expression. Nivolumab has 
been reported to be associated with pharmaco-
dynamic changes in blood and tumor markers 
that are consistent with PD-1 inhibition.12 Our 
data corroborate previous studies that have indi-
cated that higher levels of PD-L1 expression are 
associated with poorer survival in renal-cell 
carcinoma,10,11 but they do not support PD-L1 as 
a marker of treatment benefit in renal-cell carci-
noma. The relationship between PD-L1 expres-
sion and outcomes after treatment with nivolumab 
appears to depend on tumor type and histologic 
class. An association between PD-L1 expression 
and improved outcomes with nivolumab treat-
ment has been observed for metastatic melano-
ma and only some types of lung cancer.26-28
Nivolumab had a safety profile consistent 
with that seen in other studies of this drug.13-15 
Grade 3 or 4 treatment-related adverse events were 
less frequent with nivolumab than with everoli-
mus, and treatment-related adverse events leading 
to discontinuation occurred in fewer patients in 
the nivolumab group than in the everolimus 
group. Differences between treatments in the fre-
quency of specific adverse events were reflective of 
drug class. The median changes from baseline in 
the FKSI-DRS score suggested a significant and 
consistent improvement in quality of life over the 
2-year study period during nivolumab treatment.
There has been considerable progress in the 
treatment of renal-cell carcinoma since 2005, 
with five VEGF-pathway inhibitors (sorafenib, 
sunitinib, bevacizumab, pazopanib, and ax-
itinib) and two mTOR inhibitors (everolimus and 
temsirolimus) showing benefit in pivotal phase 
3 trials, which led to regulatory approval. Before 
this era, infrequent but occasionally long-stand-
ing responses were observed with cytokines, 
including high doses of interleukin-2.29 With one 
exception,30 the benefit with approved targeted 
drugs has been established in phase 3 studies 
that showed improvements in progression-free 
survival but not in overall survival with those 
drugs as compared with standard treatment, 
Event
Nivolumab Group 
(N = 406)
Everolimus Group 
(N = 397)
Any Grade Grade 3 or 4 Any Grade Grade 3 or 4
number of patients (percent)
All events 319 (79) 76 (19) 349 (88) 145 (37)
Fatigue 134 (33) 10 (2) 134 (34) 11 (3)
Nausea 57 (14) 1 (<1) 66 (17) 3 (1)
Pruritus 57 (14) 0 39 (10) 0
Diarrhea 50 (12) 5 (1) 84 (21) 5 (1)
Decreased appetite 48 (12) 2 (<1) 82 (21) 4 (1)
Rash 41 (10) 2 (<1) 79 (20) 3 (1)
Cough 36 (9) 0 77 (19) 0
Anemia 32 (8) 7 (2) 94 (24) 31 (8)
Dyspnea 30 (7) 3 (1) 51 (13) 2 (1)
Peripheral edema 17 (4) 0 56 (14) 2 (1)
Pneumonitis 16 (4) 6 (1) 58 (15) 11 (3)
Mucosal inflamma-
tion
11 (3) 0 75 (19) 12 (3)
Dysgeusia 11 (3) 0 51 (13) 0
Hyperglycemia 9 (2) 5 (1) 46 (12) 15 (4)
Stomatitis 8 (2) 0 117 (29) 17 (4)
Hypertriglyceridemia 5 (1) 0 64 (16) 20 (5)
Epistaxis 3 (1) 0 41 (10) 0
Table 2. Treatment-Related Adverse Events Reported in 10% or More of 
Treated Patients in Either Group.
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which included interferon alfa, placebo, or an 
approved antiangiogenic drug.3 Among patients 
in the phase 3 AXIS trial who had been previ-
ously treated with sunitinib, no benefit in overall 
survival was detected with axitinib as compared 
with sorafenib (median overall survival, 15.2 
months and 16.5 months, respectively).31 In addi-
tion, a phase 3 trial of cabozantinib, an investi-
gational VEGF-pathway inhibitor, showed longer 
progression-free survival with cabozantinib than 
with standard everolimus therapy in the treat-
ment of patients with previously treated renal-
cell carcinoma.32 The median overall survival of 
25.0 months with the immune checkpoint in-
hibitor nivolumab and the longer survival with 
nivolumab than with everolimus provide evidence 
of benefit in patients who have already undergone 
treatment and have advanced renal-cell carcinoma.
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